Under the NAFLD environment, the up-regulation of PPARγ is suggested to improve insulin sensitivity and glucose homeostasis, and further promote the expression of CD36 to increase the uptake of fatty acids from circulation [52,53]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.